Total revenue reached $12.1 million for Q1 2026, a 43% increase compared to $8.5 million in Q1 2025. Net loss for the quarter was $9.6 million, compared to a net loss of $6.0 million in the prior year period. Neurosurgery navigation and therapy revenue grew 80% to $5.9 million, bolstered by the IRRA flow system and new software. Cash and cash equivalents totaled $35.6 million as of March 31, 2026. The company maintains a cumulative deficit of $226.5 million since inception.